Verastem Inc Earnings

The next earnings date for Verastem Inc is August 5, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Verastem Inc Earnings

Report DateEstimated Earnings Per Share
08/05/2026$-0.45

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Verastem Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
05/07/2026After Market$-0.462.19%
02/04/2026Before Market$-0.509.78%
11/04/2025Before Market$-1.35-108.20%
08/07/2025After Market$-0.3948.42%
05/13/2025After Market$-0.79-8.89%
03/20/2025After Market$-1.33-61.47%
10/17/2024---$-0.6020.27%
08/08/2024After Market$-0.3168.10%
05/09/2024After Market$-1.26-23.94%
03/14/2024After Market$-1.02-61.29%
11/08/2023After Market$-0.7512.76%
08/08/2023After Market$-1.37-26.71%
05/09/2023After Market$-0.964.35%
03/14/2023After Market$-0.9619.97%
11/03/2022After Market$-1.0827.48%
08/08/2022Before Market$-1.44-6.95%
05/09/2022After Market$-1.08-7.60%
03/28/2022Before Market$-1.084.61%
11/04/2021After Market$-1.56-49.94%
08/02/2021After Market$-1.20-17.65%
05/11/2021After Market$-1.081.96%
03/18/2021After Market$-1.44-38.41%
11/09/2020After Market$2.64397.74%
08/10/2020Before Market$-1.686.42%
05/07/2020After Market$-4.20-54.22%
03/11/2020After Market$-6.12-9.89%
10/29/2019After Market$-4.9212.14%
08/01/2019After Market$-6.84-11.32%
05/09/2019After Market$-6.24-10.14%
03/12/2019After Market$-5.889.93%
11/07/2018After Market$-3.4832.54%
08/08/2018After Market$-3.6012.53%
05/03/2018After Market$-4.92-2.69%
03/13/2018Before Market$-5.16-0.03%
11/07/2017Before Market$-7.32-86.89%
08/08/2017After Market$-4.32-4.42%
05/10/2017After Market$-4.202.66%
03/23/2017After Market$-3.84-23.03%
11/07/2016After Market$-2.5214.22%
08/08/2016Before Market$-2.7622.69%
05/09/2016After Market$-2.6428.10%
03/03/2016Before Market$-3.8411.77%
11/09/2015Before Market$-5.045.70%
08/10/2015Before Market$-5.048.50%
05/11/2015After Market$-5.52-7.80%
03/10/2015Before Market$-6.362.33%
10/30/2014Before Market$-6.242.79%
08/07/2014After Market$-6.121.53%
05/08/2014After Market$-6.12-16.28%
03/06/2014Before Market$-5.405.12%
11/12/2013Before Market$-5.64-3.94%
08/13/2013Before Market$-5.88-17.53%
05/09/2013Before Market$-5.28-0.81%
03/27/2013Before Market$-4.688.60%
11/13/2012Before Market$-3.1228.70%
08/13/2012Before Market$-4.081.38%
05/14/2012Before Market$-5.28-51.89%
03/14/2012Before Market$-48.12-1,148.05%

More About Verastem Inc

Website
https://www.verastem.com
Country
USA
Full Time Employees
102

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

“Verastem Inc Earnings” Can Refer to the Verastem Inc Earnings Date

Some people say “Verastem Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Verastem Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Verastem Inc Stock on the Earnings Date

If you own Verastem Inc stock (VSTM) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Verastem Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Verastem Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Verastem Inc Earnings

You can contact us any time if you would like to ask questions about Verastem Inc earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.